Ignite Creation Date:
2024-05-06 @ 10:32 AM
Last Modification Date:
2024-10-26 @ 12:31 PM
Study NCT ID:
NCT03281629
Status:
COMPLETED
Last Update Posted:
2023-01-18
First Post:
2017-09-01
Brief Title:
Circuitry-Guided Smoking Cessation in Schizophrenia
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Circuitry-Guided Smoking Cessation in Schizophrenia
Status:
COMPLETED
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In a double-blinded randomized parallel controlled design patients with schizophrenia spectrum disorder will be exposed to active or sham repetitive transcranial magentic stimulation TMS which was guided by functional magnetic resonance image MRI Smoking reductioncessation and brain functional connectivity changes will be assessed at baseline different stages of rTMS andor follow-ups
Detailed Description:
Neuroimaging studies suggest that high rate of smoking in patients with schizophrenia may be due to an overlap of nicotine addiction related circuitries and schizophrenia related circuitries such that schizophrenia impact some of the same circuitries that increase risks for severe nicotine addiction in general Those identified overlapping circuitries have been linked to several key features of nicotine addiction and can be represented by resting state functional connectivities Transcranial magnetic stimulation TMS provides a non-invasive means for altering brain electrical neural activity TMS has been approved by FDA for treatment of depression Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry There are preliminarily significant improvements in treatments of smoking cessation in schizophrenia using TMS with small samples but those treatments are not robust in larger samples The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients We aim to develop a TMS method targeting special brain circuits that are both smoking cessation and schizophrenia related If the corresponding brain circuits were successfully modulated the treatment efficacy will be significantly improved and schizophrenia patients will benefit from the TMS treatment of smoking cessation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UG3DA047685 | NIH | None | httpsreporternihgovquickSearchUG3DA047685 |